Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (911-920 of 1,834) with videos related to

Pageof 184
Sort By:
Mabs|March 3, 2022
A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like propertiesJie Zhao, Liangfeng Jiang, Haodong Yang, et al.
Mabs|July 6, 2019
Glycoform-resolved FcɣRIIIa affinity chromatography-mass spectrometrySteffen Lippold, Simone Nicolardi, Elena Domínguez-Vega, et al.
Mabs|June 4, 2019
Rapid global characterization of immunoglobulin G1 following oxidative stressYao Chen, Emma Doud, Todd Stone, et al.
Mabs|June 4, 2019
Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4Katherine Griffiths, Uli Binder, William McDowell, et al.
Mabs|March 16, 2022
CLEC5a-directed bispecific antibody for effective cellular phagocytosisVivekananda Kedage, Diego Ellerman, Mingjian Fei, et al.
Mabs|February 28, 2022
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?Jingjing Zhang, Han Zhang, Litao Sun
Mabs|December 15, 2022
Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reactionFabian Bickel, François Griaud, Wolfram Kern, et al.
Mabs|May 2, 2015
Characterizing monoclonal antibody structure by carboxyl group footprintingParminder Kaur, Sara E Tomechko, Janna Kiselar, et al.
Mabs|May 2, 2015
Editorial retraction
Mabs|May 12, 2015
Regulatory considerations in oncologic biosimilar drug developmentJudith C Macdonald, Helen Hartman, Ira A Jacobs
Pageof 184

Showing results (911-920 of 1,834) with videos related to

Sort By:
Pageof 184
Mabs|March 3, 2022
A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like propertiesJie Zhao, Liangfeng Jiang, Haodong Yang, et al.
Mabs|July 6, 2019
Glycoform-resolved FcɣRIIIa affinity chromatography-mass spectrometrySteffen Lippold, Simone Nicolardi, Elena Domínguez-Vega, et al.
Mabs|June 4, 2019
Rapid global characterization of immunoglobulin G1 following oxidative stressYao Chen, Emma Doud, Todd Stone, et al.
Mabs|June 4, 2019
Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4Katherine Griffiths, Uli Binder, William McDowell, et al.
Mabs|March 16, 2022
CLEC5a-directed bispecific antibody for effective cellular phagocytosisVivekananda Kedage, Diego Ellerman, Mingjian Fei, et al.
Mabs|February 28, 2022
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?Jingjing Zhang, Han Zhang, Litao Sun
Mabs|December 15, 2022
Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reactionFabian Bickel, François Griaud, Wolfram Kern, et al.
Mabs|May 2, 2015
Characterizing monoclonal antibody structure by carboxyl group footprintingParminder Kaur, Sara E Tomechko, Janna Kiselar, et al.
Mabs|May 2, 2015
Editorial retraction
Mabs|May 12, 2015
Regulatory considerations in oncologic biosimilar drug developmentJudith C Macdonald, Helen Hartman, Ira A Jacobs
Pageof 184